{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=37",
    "query": {
      "intervention": "Part 3",
      "page": 37
    },
    "page_size": 10
  },
  "pagination": {
    "page": 37,
    "page_size": 10,
    "total_count": 4019,
    "total_pages": 402,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=38&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=36&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T21:44:26.892Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05772689",
      "title": "Caregiving While Black",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Caregiver Burden"
      ],
      "interventions": [
        {
          "name": "Usual Care",
          "type": "OTHER"
        },
        {
          "name": "Caring While Black",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2023-05-06",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-11-11T21:44:26.892Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05772689"
    },
    {
      "nct_id": "NCT06440135",
      "title": "Ziftomenib Maintenance Post Allo-HCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Myeloid Leukemia in Remission",
        "NPM1 Mutation",
        "KMT2A Rearrangement"
      ],
      "interventions": [
        {
          "name": "Ziftomenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2024-06-11",
      "completion_date": "2029-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-11-11T21:44:26.892Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Columbus, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06440135"
    },
    {
      "nct_id": "NCT06352840",
      "title": "Novel Web-based, Self-directed Intervention for Chronic Pelvic Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Pelvic Pain",
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "My Pelvic Plan Website",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Control Group website",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 70,
      "start_date": "2024-06-20",
      "completion_date": "2025-04-28",
      "has_results": true,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-11-11T21:44:26.892Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06352840"
    },
    {
      "nct_id": "NCT05831111",
      "title": "A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epstein-Barr Virus Infection"
      ],
      "interventions": [
        {
          "name": "mRNA-1195.1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1195.2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1189",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1195",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 482,
      "start_date": "2023-04-05",
      "completion_date": "2026-10-14",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-11T21:44:26.892Z",
      "location_count": 34,
      "location_summary": "Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Longmont",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05831111"
    },
    {
      "nct_id": "NCT05075564",
      "title": "A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Part 1 ES002023",
          "type": "DRUG"
        },
        {
          "name": "Part 2 ES002023",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elpiscience Biopharma, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2021-12-23",
      "completion_date": "2022-10-13",
      "has_results": false,
      "last_update_posted_date": "2025-05-14",
      "last_synced_at": "2026-11-11T21:44:26.892Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • Fayetteville, Arkansas • Los Angeles, California + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05075564"
    },
    {
      "nct_id": "NCT03944447",
      "title": "Outcomes Mandate National Integration With Cannabis as Medicine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Pain",
        "Chronic Pain Syndrome",
        "Chronic Pain Due to Injury",
        "Chronic Pain Due to Trauma",
        "Fibromyalgia",
        "Seizures",
        "Hepatitis C",
        "Cancer",
        "Crohn Disease",
        "HIV/AIDS",
        "Multiple Sclerosis",
        "Traumatic Brain Injury",
        "Sickle Cell Disease",
        "Post Traumatic Stress Disorder",
        "Tourette Syndrome",
        "Ulcerative Colitis",
        "Glaucoma",
        "Epilepsy",
        "Inflammatory Bowel Diseases",
        "Parkinson Disease",
        "Amyotrophic Lateral Sclerosis",
        "Chronic Traumatic Encephalopathy",
        "Anxiety",
        "Depression",
        "Insomnia",
        "Autism",
        "Opioid-use Disorder",
        "Bipolar Disorder",
        "Covid19",
        "SARS-CoV Infection",
        "COVID-19",
        "Corona Virus Infection",
        "Coronavirus"
      ],
      "interventions": [
        {
          "name": "Cannabis, Medical",
          "type": "DRUG"
        },
        {
          "name": "RYAH-Medtech Inhaler",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "OMNI Medical Services, LLC",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 200000,
      "start_date": "2018-12-01",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-06-02",
      "last_synced_at": "2026-11-11T21:44:26.892Z",
      "location_count": 17,
      "location_summary": "Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03944447"
    },
    {
      "nct_id": "NCT01773408",
      "title": "A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelogenous Leukemia, Acute"
      ],
      "interventions": [
        {
          "name": "RO5503781 MBP",
          "type": "DRUG"
        },
        {
          "name": "RO5503781 SDP",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2013-02",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2017-01-25",
      "last_synced_at": "2026-11-11T21:44:26.892Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Valhalla, New York • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01773408"
    },
    {
      "nct_id": "NCT03291717",
      "title": "Bridging Community Gaps Photovoice",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mental Illness",
        "Social Isolation"
      ],
      "interventions": [
        {
          "name": "Bridging Community Gaps Photovoice (BCGP)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Boston University Charles River Campus",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 197,
      "start_date": "2017-09-05",
      "completion_date": "2020-09-11",
      "has_results": false,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-11-11T21:44:26.892Z",
      "location_count": 4,
      "location_summary": "Denver, Colorado • Bridgeport, Connecticut • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Bridgeport",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Wakefield",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03291717"
    },
    {
      "nct_id": "NCT04117711",
      "title": "Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Classic Galactosemia"
      ],
      "interventions": [
        {
          "name": "AT-007",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Applied Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 114,
      "start_date": "2019-06-21",
      "completion_date": "2021-12-14",
      "has_results": true,
      "last_update_posted_date": "2024-05-30",
      "last_synced_at": "2026-11-11T21:44:26.892Z",
      "location_count": 4,
      "location_summary": "Anaheim, California • Atlanta, Georgia • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04117711"
    },
    {
      "nct_id": "NCT02425306",
      "title": "Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "6MHP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Montanide ISA-51",
          "type": "DRUG"
        },
        {
          "name": "polyICLC",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Craig L Slingluff, Jr",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2015-05-12",
      "completion_date": "2018-01-08",
      "has_results": true,
      "last_update_posted_date": "2023-10-30",
      "last_synced_at": "2026-11-11T21:44:26.892Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02425306"
    }
  ]
}